Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Sep;121(9):1693-8.
doi: 10.1016/j.ophtha.2014.03.014. Epub 2014 May 10.

Effect of early treatment with aqueous suppressants on Ahmed glaucoma valve implantation outcomes

Mohammad Pakravan  1 , Shahram Salehi Rad  2 , Shahin Yazdani  2 , Elham Ghahari  2 , Mehdi Yaseri  3
Affiliations
Randomized Controlled Trial

Effect of early treatment with aqueous suppressants on Ahmed glaucoma valve implantation outcomes

Mohammad Pakravan et al. Ophthalmology. 2014 Sep.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Ophthalmology. 2017 Jun;124(6):922. doi: 10.1016/j.ophtha.2017.03.054. Ophthalmology. 2017. PMID: 28528835 No abstract available.

Abstract

Objective: To evaluate the effect of early aqueous suppressant treatment on Ahmed glaucoma valve (AGV) surgery outcomes.

Design: Randomized clinical trial.

Participants: Ninety-four eyes of 94 patients with refractory glaucoma.

Methods: After AGV implantation, 47 cases (group 1) received topical timolol-dorzolamide fixed-combination drops twice daily when intraocular pressure (IOP) exceeded 10 mmHg, whereas 47 controls (group 2) received conventional stepwise treatment when IOP exceeded target pressure.

Main outcome measures: Main outcome measures included IOP and success rate (6 mmHg < IOP < 15 mmHg and IOP reduction of at least 30% from baseline). Other outcome measures included best-corrected visual acuity, complications, and hypertensive phase frequency.

Results: Groups 1 and 2 were both followed up for a mean of 45±11.6 and 47.2±7.4 weeks, respectively (P = 0.74). Mixed model analysis revealed a significantly greater IOP reduction in group 1 at all intervals (P<0.001). At 1 year, the cases exhibited a significantly higher success rate (63.2% vs. 33.3%; P = 0.008) and reduced hypertensive phase frequency (23.4% vs. 66.0%; P<0.001).

Conclusions: Early aqueous suppressant treatment may improve AGV implantation outcomes in terms of IOP reduction, success rate, and hypertensive phase frequency.

PubMed Disclaimer

Comment in

Publication types

MeSH terms